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ABSTRACT
Background. Whether gastrectomy with D2 lymphade-
nectomy improves survival of patients with advanced gastric
cancer (AGC) remains controversial. Few studies have
described the pathological features of AGC with metastatic
suprapancreatic lymph nodes (LN), which are the target of
D2 lymphadenectomy. This study therefore aims to clarify
the prognosis and clinical pathological features including the
number and location of metastatic LN in AGC with meta-
static suprapancreatic LN.
Methods. 406 patients with AGC, who underwent gas-
trectomy with D2 lymphadenectomy from 1982 to 2007 at
Oita University, were reviewed retrospectively with regard
to presence or absence of metastatic suprapancreatic LN.
The pathological factors associated with AGC with meta-
static suprapancreatic LN were examined by univariate and
multivariate analysis.
Results. Of 362 patients with AGC, 78 had suprapancreatic
LN metastasis (21.5 %), differing significantly in terms of
presence of vascular invasion and having a larger number of
metastatic perigastric LN in comparison with only meta-
static perigastric LN on univariate analysis. According to
multivariate analysis, they were associated with presence of
vascular invasion and a large number of total metastatic LN
(more than two; N2B). The overall 5-year survival rate of
the AGC with perigastric LN metastasis (station 1–7) group
was 37.9 % and of the AGC with suprapancreatic LN
metastasis group was 12.8 %. There were significant dif-
ferences in each group (P \ 0.05).
Conclusions. Patients with AGC with metastatic supra-
pancreatic LN had a large number of total metastatic LN
and poor prognosis, suggesting that it may be a systemic
disease.
Gastric cancer is one of the most prevalent malignant
tumors worldwide. Improvements in diagnostic modalities,
such as endoscopy and barium examinations, have
increased the incidence of early gastric cancer (EGC),
whereas advanced gastric cancer (AGC) with poor prog-
nosis has not decreased.
It is widely accepted that the most effective strategy for
AGC is surgical treatment. The purpose of surgery for AGC is
complete clearance of local cancer cells (R0), which involves
both gastrectomy and lymphadenectomy. However, the opti-
mal extent of lymphadenectomy for AGC is still under
discussion. In Asian countries, gastrectomy with extended
(D2) lymphadenectomy has been performed as a standard
procedure for AGC, whereas gastrectomy with perigastric
(D1) lymphadenectomy has been used in Western countries.
Although randomized controlled trials to clarify the benefits of
D2 lymphadenectomy for survival have been carried out in
Germany, the UK, and Taiwan, a consensus has not been
reached.1–9 Dissection of suprapancreatic lymph nodes (LN)
is the main difference between D1 and D2 lymphadenectomy.
However, few studies have described the pathological features
or prognosis of AGC with metastatic suprapancreatic LN.
It was recently acknowledged that the total number of
metastatic LN is a more reliable prognostic indicator than
positive anatomical lymphatic stations.10–15 Therefore, in
the tumor–node–metastasis (TNM) classification, the total
number of metastatic LN was adopted to classify the stages
of gastric cancer. Most AGC with more than six metastatic
LN (N3) appear to be systemic disease because of poor
prognosis, and the prognosis of AGC patients with meta-
static suprapancreatic LN is known to be very poor, even
after curative (R0) surgery.16 There is a possibility that
they have a larger number of total metastatic LN.
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The aim of this study is to clarify the prognosis and
clinical pathological features including the number and
location of metastatic LN in AGC with metastatic supra-
pancreatic LN.
PATIENTS AND METHODS
From January 1982 to December 2007, 362 patients with
AGC underwent initial gastrectomy at the Department of
Surgery I, Oita University Faculty of Medicine. Among
them, we studied 165 patients with AGC with metastatic
LN who underwent gastrectomy with D2 lymphadenec-
tomy and with complete follow-up for 5 years after
gastrectomy. The type of gastrectomy was determined
according to the Japanese Guidelines for Diagnosis and
Treatment of Carcinoma of the Stomach. Although we
have introduced laparoscopy-assisted distal gastrectomy
for such patients since 1994, the operative criteria have not
been changed in our institution.17
The age and sex of the patients, the location, size, gross
type, histological type, depth of wall invasion, and extent
of lymphatic and vascular invasion of the AGC, and the
number of positive LN were obtained from surgery and
pathology records. These pathological findings were ana-
lyzed according to the Japanese Classification of Gastric
Carcinoma, and the cancer stage was assessed according to
the Union for International Cancer Control (UICC) TNM
Classification of Malignant Tumors, 7th edition.18 To avoid
sample bias, more than 14 LN were dissected from en bloc
specimens and their classification was determined by sur-
geons and pathologists shortly after surgery, based on the
Japanese Classification of Gastric Carcinoma. The pres-
ence of LN metastases was decided by pathologists using
hematoxylin–eosin-stained specimens of a maximum sec-
tion of the surface of the LN. The pathology records were
reported by pathologists. We categorized suprapancreatic
LN as those along the common hepatic artery (station 8a),
around the celiac artery (station 9), along the proximal
splenic artery (station 11p), and around the proper hepatic
artery (station 12a).
First, the incidence of metastatic suprapancreatic LN in
patients with AGC was reviewed. Next, the pathological
features of AGC with metastatic suprapancreatic LN were
determined. We divided AGC with metastatic LN into two
groups: those with (n = 78) and those without (n = 87)
metastatic suprapancreatic LN.
Postoperatively, patients were examined at follow-up
visits every 3 months for the first 2 years and every
6 months thereafter. At each follow-up control, carcino-
embryonic antigen and carbohydrate antigen 19-9 level
were determined. Thoracicoabdominal and pelvic com-
puted tomographic scan or abdominal ultrasonography was
performed alternately every 3–6 months. Gastroscopy was
performed yearly.
We then compared their pathological features using the
Chi-square test. The Wilcoxon rank test was performed for
median age and tumor size comparison. Multivariate
analysis was used for adjusting the odds ratio and corre-
sponding 95 % confidence interval. Cumulative probability
of overall survival (OS) was estimated by Kaplan–Meier
survival methods, and differences between subgroups were
assessed by the log-rank test. Duration of follow-up was
calculated as the time from surgery to the event of death.
The reason for studying only OS was incomplete follow-up
in some patients and consequent limitation of sample size
as described above. Variables for which the P value on
univariate analysis was less than 0.05 were included in
subsequent multivariate analysis. P \ 0.05 was considered
to be statistically significant for all analyses.
All statistical analysis was performed using SPSS 11.0
statistics software. This study was conducted according to
the Ethical Guidelines for Clinical Studies of Oita Uni-
versity Faculty of Medicine.
RESULTS
In this study, the incidence of AGC with metastatic LN
was 75.7 % (165/218) of all AGC, with a mean number of
metastatic LN of 9.9 ± 9.8. The rate of AGC with meta-
static LN in the suprapancreatic area was approximately
35.8 % (78/218) of all AGC with metastatic LN, with a
mean number of metastatic LN of 14.8 ± 11.6, which was
significantly higher than that in AGC without metastatic
suprapancreatic LN. Among these, 50 cases (64.1 %) had
two or more metastatic LN in the suprapancreatic area,
with a mean number of total metastatic LN of 18.8 ± 12.2.
The incidence of metastatic suprapancreatic LN increased
according to the depth of cancer: 7.7 % in T2 cancers,
25.6 % in T3, and 66.7 % in T4. Their frequency was not
affected by the location of the cancer. The incidence of
skip metastasis to suprapancreatic LN was only 2.6 % in
AGC with metastatic LN.
The median follow-up period of this study was
75 months. The median follow-up period was 74 months in
the no metastatic LN (N0) group, 76 months in the peri-
gastric LN metastasis (station 1–7) group, and 71.5 months
in the suprapancreatic LN metastasis group. The overall
5-year survival rate of AGC in our study is shown in Fig. 1.
The 5-year survival rate of the AGC without LN metastasis
(N0) group was 52.8 % and of the AGC with only peri-
gastric LN metastasis (station 1–7) group was 37.9 %; on
the other hand, in the AGC with suprapancreatic LN
metastasis group, it was 12.8 %. There were significant
differences in each group (P \ 0.05). Our study showed
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that the recurrence rates in the AGC with suprapancreatic
LN metastasis group were 20.0 % for hematogenous
metastasis, 5.0 % for metastasis to locoregional area,
25.0 % for paraaortic LN metastasis, and 50.0 % for per-
itoneal dissemination, whereas the recurrence rates in the
AGC with only perigastric LN metastasis group were 24.3,
13.5, 13.5, and 48.7 %, respectively.
No significant differences were observed in patient sex
or age or the surgical procedure between AGC with and
without metastatic LN in the suprapancreatic area
(Table 1), and the mean number of suprapancreatic LN
harvested did not differ between the two groups. There was
no significant difference in the location, size of tumor,
gross type, histological type, depth of invasion, and extent
of lymphatic invasion of the cancer between the groups. In
the present study, the following pathological features of
AGC with metastatic suprapancreatic LN were determined
in comparison with AGC without such LN by univariate
analysis: presence of vascular invasion, larger number of
metastatic perigastric LN, and more advanced stage of
cancer (Table 2). Detailed examination of AGC with
metastatic suprapancreatic LN showed a larger number of
total metastatic LN and also a larger number of metastatic
LN along either the lesser curvature or the greater curva-
ture (Table 3).
Subsequent multivariate analysis using these significant
factors showed that presence of vascular invasion and
larger number of metastatic LN (more than two nodes;
N2B) were associated with AGC with metastatic supra-
pancreatic LN (Table 4).
DISCUSSION
Whether gastrectomy with D2 lymphadenectomy improves
survival of patients with AGC remains controversial. In Asian
countries, gastrectomy with D2 lymphadenectomy has been
performed as a standard procedure for AGC, whereas in
Western countries, gastrectomy with D1 lymphadenectomy
has been performed. Dissection of suprapancreatic LN is the
FIG. 1 Kaplan–Meier survival analysis of advanced gastric cancer
with no metastatic lymph nodes or with/without metastatic suprapan-
creatic lymph nodes (log-rank test). The 5-year OS was 52.8 % in
patients with no metastatic lymph nodes (n = 53), 37.9 % in patients
without metastatic suprapancreatic lymph nodes (n = 87), and
12.8 % in patients with metastatic suprapancreatic lymph nodes
(n = 78). Survival rate after gastrectomy with D2 lymphadenectomy
for AGC was significantly worse in patients with metastatic
suprapancreatic lymph nodes than in those without (P \ 0.05)
TABLE 1 Clinicopathologic features of patients with advanced gastric cancer with and without metastatic suprapancreatic lymph nodes
Clinicopathologic variable Metastatic suprapancreatic lymph nodes P value
Present (n = 78) Absent (n = 87)
Sex 0.12
Male 59 (75.6 %) 56 (64.4 %)





TG 48 (61.5 %) 51 (58.6 %)
DG 30 (38.5 %) 36 (41.4 %)
Average dissected lymph nodes 0.95
Total number 35.5 (7–88) 32.3 (8–67)
Lesser curvature (station 1, 3, 5, 7) 13.8 (2–37) 14.3 (0–30)
Greater curvature (station 2, 4, 6) 11.7 (0–27) 11.1 (0–33)
Suprapancreatic lymph nodes 10.0 (1–28) 6.9 (1–23)
TG total gastrectomy, DG distal gastrectomy
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main difference between D1 and D2 lymphadenectomy.
Because only a few studies have examined them previously,
we investigated the prognosis and clinical pathological fea-
tures of AGC associated with metastatic suprapancreatic LN.
The present study showed that suprapancreatic LN
metastasis occurred in approximately 35.8 % of AGC with
metastatic LN, with a mean number of total metastatic LN
of 14.8 ± 11.6. Subsequent multivariate analysis showed
that presence of vascular invasion and LN metastasis
(N2B) were independent pathological factors associated
with AGC with metastatic suprapancreatic LN. Thus, most
AGC with metastatic suprapancreatic LN appear to be at a
very advanced stage.
This study was retrospective and was conducted at a
single institution. That is why we had to exclude 197 cases
whose follow-up was not complete. In addition, analysis of
the survival curve included only OS because of sample size
limitation and incompleteness of recurrence data. In the
present study, the quantity of metastatic cancer cells in
each LN was not evaluated, and micrometastasis and ex-
tranodal metastasis were not examined.
TABLE 2 Pathological features of the tumor in advanced gastric











U 24 (30.8 %) 33 (38.0 %)
M 32 (41.0 %) 27 (31.0 %)
L 22 (28.2 %) 27 (31.0 %)




Type 1 ? 2 25 (32.1 %) 34 (39.1 %)
Type 3?4 53 (67.9 %) 53 (60.9 %)
Histological type 0.28
Well/moderately 25 (32.1 %) 35 (40.2 %)
Poorly 53 (67.9 %) 52 (59.8 %)
Depth of invasion 0.090
T2 6 (7.7 %) 13 (14.9 %)
T3 20 (25.6 %) 32 (36.8 %)
T4 52 (66.7 %) 42 (48.3 %)
Lymphatic invasion 0.39
Present 75 (96.2 %) 81 (93.1 %)
Absent 3 (3.8 %) 6 (6.9 %)
Vascular invasion \0.05
Present 50 (64.1 %) 41 (47.1 %)
Absent 28 (35.9 %) 46 (52.9 %)
Lymph node metastasis \0.01
N1 3 (3.8 %) 30 (34.5 %)
N2 18 (23.1 %) 30 (34.5 %)




IIA 1 (1.3 %) 6 (6.9 %)
IIB 3 (3.8 %) 18 (20.7 %)
IIIA 11 (14.1 %) 19 (21.8 %)
IIIB 8 (10.3 %) 19 (21.8 %)
IIIC 55 (70.5 %) 25 (28.8 %)
TABLE 3 Number of perigastric lymph nodes in advanced gastric
cancer with and without metastatic suprapancreatic lymph nodes












Present 76 (97.4 %) 87 (100 %)
Absent 2 (2.6 %) 0 (0 %)
Number \0.01
n = 0 2 (2.6 %) 0 (0 %)
1 B n B 2 8 (10.3 %) 30 (34.5 %)
3 B n B 6 17 (21.7 %) 30 (34.5 %)
7 B n B 15 33 (42.3 %) 22 (25.3 %)
16 B n 18 (23.1 %) 5 (5.7 %)
Lesser curvature (station 1, 3,
5, 7)
0.80
Present 70 (89.7 %) 77 (88.5 %)
Absent 8 (10.3 %) 10 (11.5 %)
Number \0.01
n = 0 8 (10.3 %) 10 (11.5 %)
1 B n B 2 14 (17.8 %) 31 (35.6 %)
3 B n B 6 25 (32.1 %) 34 (39.1 %)
7 B n B 15 24 (30.8 %) 10 (11.5 %)
16 B n 7 (9.0 %) 2 (2.3 %)
Greater curvature (station 2,
4, 6)
\0.01
Present 65 (83.3 %) 49 (56.3 %)
Absent 13 (16.7 %) 38 (43.7 %)
Number \0.01
n = 0 13 (16.7 %) 38 (43.7 %)
1 B n B 2 22 (28.2 %) 28 (32.2 %)
3 B n B 6 19 (24.4 %) 11 (12.6 %)
7 B n B 15 23 (29.4 %) 10 (11.5 %)
16 B n 1 (1.3 %) 0 (0 %)
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Many studies have been conducted in Japan on the flow
of lymphoid fluid and the distribution of the LN along the
stomach to determine how gastric cancer cells spread
through lymphatic vessels.19–21 Cancer cells from the pri-
mary lesion flow through the lymphoid vessels and produce
an embolus in the LN, after which metastatic LN are
formed according to a regular probability. Lee et al.
showed that skip metastasis to the suprapancreatic LN
occurred in 2.8 % of EGCs.22 In the present study, the
incidence of skip metastasis to the suprapancreatic LN was
only 2.6 % in AGC. Therefore, the frequency of skip
metastasis in AGC and EGC was similar. Skip metastasis
may be a phenomenon that occurs relatively early with a
small number of cancer cells in the lymphatic vessel.
The risk factors for LN metastases in gastric cancer have
been identified as the depth, size, and histological type of
cancer.23–25 In the seventh edition of the UICC classifica-
tion, the number of metastatic LN was adopted as an index
of the stages of a disease. Katai et al. reviewed the char-
acteristics of LN metastasis in 1,230 gastric cancers,
including EGC, and showed that gastric cancer with met-
astatic suprapancreatic LN was associated with a large
number of metastatic perigastric LN ([3 positive nodes).26
Our result that a larger number of metastatic LN (N2B)
was associated with AGC with metastatic LN supports their
study. Adachi et al. showed that the prognosis of patients
with two or more metastatic suprapancreatic LN, including
those around the left gastric artery, was extremely poor.16
Our preliminary data show that a considerably higher
number of total metastatic LN (N3b) is associated with
AGC with two or more metastatic suprapancreatic LN
(data not shown).
Our data showed extremely poor prognosis in the AGC
with suprapancreatic LN metastasis group. The 5-year
survival rate in this study was 12.8 % for the AGC with
suprapancreatic LN metastasis group. According to the
annual report of the Japanese Gastric Cancer Association
(JGCA), 2008, 13th edition, the 5-year survival rates for
AGC were 91.9 % for stage IA, 85.1 % for stage IB,
73.1 % for stage II, 51.0 % for stage IIIA, 33.4 % for stage
IIIB, and 15.8 % for stage IV.27 According to the JGCA
criteria, T4 ± N0, T3 ? N1, and T2 ? N2 constitute stage
IIIA whereas T4 ? N1 and T3 ? N2 constitute stage IIIB.
However, our study included these cases and stage IV cases
with grading such as T2 ? N3, T3 ? N3, T4 ? N2, and
T4 ? N3. We consider that the difference in criteria
between JGCA and our study was the reason for the poor
prognosis in this study.
Some studies have reported the recurrence patterns of
gastric cancer. Ho et al. reported that the recurrence rates
of EGC with metastasis to distant, locoregional, and peri-
toneal area were 55.7, 34, and 10.3 %, respectively.28 The
liver was the most common site of recurrence in distant
metastasis. Moriguchi et al. reported that the recurrence
rates of AGC with metastasis to distant, locoregional,
peritoneal, and other sites were 35.7, 11.3, 31.5, and
21.5 %, respectively.29 In our study, the locoregional
recurrence rate in the perigastric LN metastasis group was
similar to the rate observed in the study by Moriguchi et al.
However, our data showed that there were very few loco-
regional recurrences in the suprapancreatic LN metastasis
group. The peritoneal area was the most common site of
recurrence, and the second most common site was the
paraaortic LN area in the suprapancreatic LN metastasis
group. These findings suggest that AGC with suprapan-
creatic LN metastasis has poor prognosis.
Whether gastrectomy with D2 lymphadenectomy
improves survival of patients with AGC compared with
gastrectomy with D1 lymphadenectomy is controversial.
The Dutch trial and British Medical Research Council trial
failed to show a benefit of gastrectomy with D2 lymphade-
nectomy for survival, but rather showed that this procedure
increased the rate of complications, such as pancreatic
juice.1–5,7, 8 Macroscopic metastasis and micrometastasis to
the LN around the left gastric artery (station 7) and supra-
pancreatic area might be causes of such a result. D1
lymphadenectomy in these studies is perigastric LN dissec-
tion, and it is different from D1 lymphadenectomy in the
latest Japanese gastric cancer treatment guidelines (2010).27
In other words, D1 lymphadenectomy includes station 7 in
the Japanese gastric cancer treatment guidelines of 2010.
Station 7 is LN in the mesentery, and it is necessary to
examine the significance of metastasis to station 7. On the
other hand, a randomized trial in Taiwan demonstrated an
improved survival of 6 % after D2/3 lymphadenectomy
compared with D1 lymphadenectomy.9 Moreover, accord-
ing to the long-term (15 years) results of a randomized
nationwide Dutch D1/D2 trial, not OS but the disease-free
survival rate was shown to improve after D2 lymphadenec-
tomy.30 Therefore, the guidelines of the European Society
for Medical Oncology and the National Comprehensive
TABLE 4 Results of multivariate analyses of clinicopathologic
factors in advanced gastric cancer with and without metastatic
suprapancreatic lymph nodes
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Cancer Network have been amended to recommend D2
lymphadenectomy as the standard treatment procedure.
When metastasis to suprapancreatic LN in AGC is unclear by
preoperative diagnosis and if the operative complications of
D1 and D2 lymphadenectomy are similar, D2 lymphade-
nectomy is recommended as a standard procedure. However,
for AGC with defined suprapancreatic LN metastasis, pre-
operative chemotherapy might be recommended.
In this study, metastatic suprapancreatic LN were
examined and station 7 was not examined. The presence of
more than two total metastatic LN and vascular invasion
were associated with AGC with metastatic suprapancreatic
LN, which accounted for 35.8 % of all AGC. AGC with
metastatic suprapancreatic LN had a larger number of total
metastatic LN, suggesting that the prognosis of patients
with this disease was extremely poor. This may be a reason
why it is difficult to prove the benefits of gastrectomy with
D2 lymphadenectomy for survival of patients with AGC.
Therefore, further multicenter studies are required to con-
firm the prognosis and clinicopathological characteristics of
AGC with metastasis to suprapancreatic LN. Additionally,
micrometastasis, the molecular biological characteristics of
AGC with metastatic suprapancreatic LN, and circulating
cancer cells are required to clarify the clinical significance
of suprapancreatic metastasis in the near future.
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